78
Views
0
CrossRef citations to date
0
Altmetric
Letter to the Editor: Response to a Published Article

Comment on Durrani et al.’s “Adalimumab for Ocular Inflammation”

, MD & , PhD
Page 70 | Received 26 Jul 2017, Accepted 21 Aug 2017, Published online: 11 Oct 2017
 
This article refers to:
Adalimumab for Ocular Inflammation
This article is referred to by:
Authors Reply to Letter to the Editor– In Response to: Comment on Durrani et al.’s “Adalimumab for Ocular Inflammation”

Declaration of interest

The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.